NPC Archive Item: July Drug Safety Update from MHRA/CHM

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The Drug Safety Update is an NHS Evidence accredited provider 7th July 2009 The MHRA and CHM have published the July edition of Drug Safety Update. This issue gives […]

NPC Archive Item: Swine flu: reporting suspected adverse reactions to oseltamivir▼, zanamivir▼ and future vaccines

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 7th July 2009 The MHRA has set up the Swine Flu ADR Portal to monitor the safety of oseltamivir▼ (Tamiflu) and zanamivir▼ (Relenza) as their use increases during the […]

NPC Archive Item: NPSA Review of patient safety for children and young people

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Published in June 2009 by the National Patient Safety Agency (NPSA), the review of patient safety for children and young people highlights some of the patient safety issues for […]

NPC Archive Item: June Drug Safety Update from MHRA/CHM

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The Drug Safety Update is an NHS Evidence accredited provider 11th June 2009 The MHRA and CHM have published the June edition of Drug Safety Update. This issue gives […]

NPC Archive Item: EMEA statement on possible interaction between clopidogrel and proton pump inhibitors

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 4th June 2009 Concomitant use of proton pump inhibitors (PPIs) and clopidogrel is not advisable unless absolutely necessary, the EU Committee for Medicinal products for Human Use (CHMP) and […]

NPC Archive Item: The Contribution of Pharmacy to Making Britain a Safer Place to Take Medicines

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 20th March 2009 Introduction: In the publication ‘The Contribution of Pharmacy to Making Britain a Safer Place to Take Medicines’, the Royal Pharmaceutical Society of Great Britain (RPSGB) revisits […]

NPC Archive Item: FDA investigates possible safety concerns over clopidogrel

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 4th February 2009 The US Food and Drug Administration has published information about an ongoing safety review of clopidogrel. This follows reports suggesting it is less effective in some […]

NPC Archive Item: EMEA recommendations for safer use of methylphenidate-containing medicines

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 4th February 2009 The EMEA’s Committee for Medicinal Products for Human Use (CHMP) has reviewed methylphenidate due to concerns over cardiovascular and cerebrovascular risks. They also considered the risk […]

NPC Archive Item: New guidance launched to improve patient care in general practice

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Introduction At the beginning of October the NPSA launched new guidance for general practice teams enabling them to learn from both positive and negative significant events. This includes such […]

NPC Archive Item: Rimonabant marketing authorisation to be suspended

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The MHRA has announced the Europe-wide suspension of the Marketing Authorisation for rimonabant▼ (Acomplia®) following recommendations from the EMEA’s Committee for Medicinal Products for Human Use (CMHP). The CMHP […]